Your browser doesn't support javascript.
loading
Risankizumab for the treatment of genital psoriasis: A 1-year, real-world experience.
Orsini, D; Frascione, P; Assorgi, C; Pacifico, A; Sperduti, I; Gargiulo, L; Ibba, L; Valenti, M; Costanzo, A; Narcisi, A.
Affiliation
  • Orsini D; Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
  • Frascione P; Dermatology Oncology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
  • Assorgi C; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Pacifico A; Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
  • Sperduti I; Biostatistical Unit, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy.
  • Gargiulo L; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy.
  • Ibba L; Department of Biomedical Sciences, Humanitas University, Italy.
  • Valenti M; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy.
  • Costanzo A; Department of Biomedical Sciences, Humanitas University, Italy.
  • Narcisi A; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy.
J Eur Acad Dermatol Venereol ; 38(3): e256-e258, 2024 Mar.
Article in En | MEDLINE | ID: mdl-37795669
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Antibodies, Monoclonal Aspects: Patient_preference Limits: Humans Language: En Journal: J Eur Acad Dermatol Venereol Year: 2024 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Antibodies, Monoclonal Aspects: Patient_preference Limits: Humans Language: En Journal: J Eur Acad Dermatol Venereol Year: 2024 Document type: Article